CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 256 enrolled
Drug / intervention
erlotinib +1 moredrug
Likely dose
erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01024413
NCT01024413Phase 3Completed
CompareCT.gov

A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations

Chinese Society of Lung Cancer·interventional·Posted Dec 2, 2009·Updated Mar 1, 2017

In Brief

A Phase 3 clinical trial evaluating erlotinib and gefitinib for Thoracic Neoplasms. Completed, enrolled 256 participants across 1 site.

Detailed Summary

This is a randomized controlled trial to compare efficacy and safety between erlotinib and gefitinib in advanced NSCLC harboring EGFR exon 19 or 21 mutations.Eligible patients were randomized to receive erlotinib or gefitinib in any line settings.The primary endpoint was progression-free survival (PFS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThoracic Neoplasms
CountriesChina
CollaboratorsGuangdong Provincial People's Hospital

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2, 2009
Enrollment StartJul 1, 2009
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 16.6 years ago

Interventions

erlotinibdrug

study arm.erlotinib 150 mg oral till disease progression

gefitinibdrug

study arm.gefitinib 250 mg oral till disease progression